Clinical Trial Update: SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) [Phase 3]

View source ↗

Summary

SPIRIT III was a Phase 3 study evaluating the XIENCE V everolimus-eluting coronary stent system; the trial completed and results were posted in 2008.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Restenosis
• Myocardial Ischemia
• Total Occlusion of the Coronary Artery

Drugs mentioned

• Everolimus (everolimus)
• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Stents, Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2008-12-15